Gilead Sciences Inc. (GILD)

Gilead Sciences Inc. (GILD $122.74)
- $122.74 P/E (TTM): 18.33X Cap: $152.28B
- View GILD Profile
- View Questions on GILD

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Gilead Sciences Inc. (GILD $122.74)
- $122.74 P/E (TTM): 18.33X Cap: $152.28B
- View GILD Profile
- View Questions on GILD
Abbott Laboratories (ABT $125.29)
- $125.29 P/E (TTM): 15.61X Cap: $217.86B
- View ABT Profile
- View Questions on ABT
Merck & Company Inc. (MRK $105.26)
- $105.26 P/E (TTM): 11.28X Cap: $261.25B
- View MRK Profile
- View Questions on MRK
Pfizer Inc. (PFE $24.90)
- $24.90 P/E (TTM): 14.33X Cap: $141.57B
- View PFE Profile
- View Questions on PFE

Q: Would you recommend starting a new position now in these big pharma stocks with rotation out of the tech sector lately? All three have decent PE, PEG and PS ratios and have been fared well in last few bear markets overall. What would your recommended allocation be across the three stocks for an investment of time line of 5 years?
Thanks!

Read Answer Asked by Scott on December 17, 2025

Amgen Inc. (AMGN $327.31)
- $327.31 P/E (TTM): 22.94X Cap: $176.25B
- View AMGN Profile
- View Questions on AMGN
Gilead Sciences Inc. (GILD $122.74)
- $122.74 P/E (TTM): 18.33X Cap: $152.28B
- View GILD Profile
- View Questions on GILD
AbbVie Inc. (ABBV $228.49)
- $228.49 P/E (TTM): 166.44X Cap: $403.82B
- View ABBV Profile
- View Questions on ABBV
Abbott Laboratories (ABT $125.29)
- $125.29 P/E (TTM): 15.61X Cap: $217.86B
- View ABT Profile
- View Questions on ABT
The Cigna Group (CI $275.23)
- $275.23 P/E (TTM): 10.73X Cap: $73.52B
- View CI Profile
- View Questions on CI
Johnson & Johnson (JNJ $206.95)
- $206.95 P/E (TTM): 18.01X Cap: $498.60B
- View JNJ Profile
- View Questions on JNJ
Medtronic plc. (MDT $96.06)
- $96.06 P/E (TTM): 24.51X Cap: $123.15B
- View MDT Profile
- View Questions on MDT
Savaria Corporation (SIS $22.78)
- $22.78 P/E (TTM): 25.67X Cap: $1.63B
- View SIS Profile
- View Questions on SIS
- View Reports on SIS

Q: I am mostly content with my health care stocks with the exception of MDT. It has been essentially flat since about 2016 except for the dividend. It did peak around 2022 but has fallen down to previous levels.
What do you think of the longer term for MDT?
Would you make any other changes for slow but reliable growth and higher end of dividends.
As always, thank you for the great service.

Read Answer Asked by Tulio on August 21, 2025

Gilead Sciences Inc. (GILD $122.74)
- $122.74 P/E (TTM): 18.33X Cap: $152.28B
- View GILD Profile
- View Questions on GILD
Intuitive Surgical Inc. (ISRG $566.36)
- $566.36 P/E (TTM): 71.02X Cap: $200.77B
- View ISRG Profile
- View Questions on ISRG
AbbVie Inc. (ABBV $228.49)
- $228.49 P/E (TTM): 166.44X Cap: $403.82B
- View ABBV Profile
- View Questions on ABBV
Johnson & Johnson (JNJ $206.95)
- $206.95 P/E (TTM): 18.01X Cap: $498.60B
- View JNJ Profile
- View Questions on JNJ
Eli Lilly and Company (LLY $1,074.68)
- $1,074.68 P/E (TTM): 41.32X Cap: $1.01T
- View LLY Profile
- View Questions on LLY
Medtronic plc. (MDT $96.06)
- $96.06 P/E (TTM): 24.51X Cap: $123.15B
- View MDT Profile
- View Questions on MDT
Stryker Corporation (SYK $351.47)
- $351.47 P/E (TTM): 47.93X Cap: $134.41B
- View SYK Profile
- View Questions on SYK
Thermo Fisher Scientific Inc (TMO $579.45)
- $579.45 P/E (TTM): 31.97X Cap: $217.70B
- View TMO Profile
- View Questions on TMO
State Street Health Care Select Sector SPDR ETF (XLV $154.80)
- $154.80 P/E (TTM): 24.15X Cap: $39.70B
- View XLV Profile
- View Questions on XLV
iShares U.S. Medical Devices ETF (IHI $62.15)
- $62.15 P/E (TTM): 30.27X Cap: $4.03B
- View IHI Profile
- View Questions on IHI
Sabra Health Care REIT Inc. (SBRA $18.94)
- $18.94 P/E (TTM): 24.4X Cap: $4.68B
- View SBRA Profile
- View Questions on SBRA
Healthcare Realty Trust Incorporated (HR $16.95)
- $16.95 Cap: $5.94B
- View HR Profile
- View Questions on HR
iShares U.S. Pharmaceuticals ETF (IHE $84.83)
- $84.83 P/E (TTM): 22.53X Cap: $852M
- View IHE Profile
- View Questions on IHE
Catalyst Pharmaceuticals Inc. (CPRX $23.34)
- $23.34 P/E (TTM): 11.97X Cap: $2.86B
- View CPRX Profile
- View Questions on CPRX

Q: There was an article in the Globe and Mail today by David Rosenberg about the aging population and he suggested health care related investments such as health care REITS, pharma, devices, and services. What do you think of this idea and can you give me a few recommendations in canada and the US for each of the 4 categories (health reits, pharma, devices, sefrvices)? A mix of ETFS and individual stocks would be great.

Read Answer Asked by Carla on July 08, 2025